Medical treatment guidelines for preventive treatment of migraine

Tzu Chou Huang, Tzu Hsien Lai, Shuu Jiun Wang, Po Jen Wang, Yen Feng Wang, Lien Huei Lee, Kao Chang Lin, Zin An Wu, Ching Sen Shih, Yung Chu Hsu, Yen Yu Chen, Wei Hung Chen, Wei Ta Chen, Ping Kun Chen, Tzu Chou Huang, Jong Ling Fu, Chun Pai Yang, Tu Hsueh Yeh, Yi Chu Liao, Tzu Hsien LaiJing Jane Tsai, Shiang Ru Lu, Treatment Guideline Subcommittee of Taiwan Headache Society

研究成果: 雜誌貢獻文章同行評審

19 引文 斯高帕斯(Scopus)


The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the “start low and go slow” doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.
頁(從 - 到)33-35
期刊Acta Neurologica Taiwanica
出版狀態已發佈 - 1月 1 2017

ASJC Scopus subject areas

  • 神經內科
  • 神經病學(臨床)


深入研究「Medical treatment guidelines for preventive treatment of migraine」主題。共同形成了獨特的指紋。